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Background: Cefadroxil, a cephalosporin antibiotic, is a substrate for several membrane transporters including
peptide transporter 2 (PEPT2), organic anion transporters (OATs), multidrug resistance-associated proteins (MRPs),
and organic anion transporting polypeptides (OATPs). These transporters are expressed at the blood–brain barrier
(BBB), blood-cerebrospinal fluid barrier (BCSFB), and/or brain cells. The effect of these transporters on cefadroxil
distribution in brain is unknown, especially in the extracellular and intracellular fluids within brain.
Methods: Intracerebral microdialysis was used to measure unbound concentrations of cefadroxil in rat blood,
striatum extracellular fluid (ECF) and lateral ventricle cerebrospinal fluid (CSF). The distribution of cefadroxil in brain
was compared in the absence and presence of probenecid, an inhibitor of OATs, MRPs and OATPs, where both
drugs were administered intravenously. The effect of PEPT2 inhibition by intracerebroventricular (icv) infusion of
Ala-Ala, a substrate of PEPT2, on cefadroxil levels in brain was also evaluated. In addition, using an in vitro brain slice
method, the distribution of cefadroxil in brain intracellular fluid (ICF) was studied in the absence and presence of
transport inhibitors (probenecid for OATs, MRPs and OATPs; Ala-Ala and glycylsarcosine for PEPT2).
Results: The ratio of unbound cefadroxil AUC in brain ECF to blood (Kp,uu,ECF) was ~2.5-fold greater during
probenecid treatment. In contrast, the ratio of cefadroxil AUC in CSF to blood (Kp,uu,CSF) did not change significantly
during probenecid infusion. Icv infusion of Ala-Ala did not change cefadroxil levels in brain ECF, CSF or blood.
In the brain slice study, Ala-Ala and glycylsarcosine decreased the unbound volume of distribution of cefadroxil in
brain (Vu,brain), indicating a reduction in cefadroxil accumulation in brain cells. In contrast, probenecid increased
cefadroxil accumulation in brain cells, as indicated by a greater value for Vu,brain.
Conclusions: Transporters (OATs, MRPs, and perhaps OATPs) that can be inhibited by probenecid play an important
role in mediating the brain-to-blood efflux of cefadroxil at the BBB. The uptake of cefadroxil in brain cells involves both
the influx transporter PEPT2 and efflux transporters (probenecid-inhibitable). These findings demonstrate that drug-drug
interactions via relevant transporters may affect the distribution of cephalosporins in both brain ECF and ICF.
Keywords: Blood–brain barrier, Blood-cerebrospinal fluid barrier, Intracerebral microdialysis, Brain slice, Cefadroxil,
Multidrug resistance-associated proteins, Organic anion transporters, Organic anion transporting polypeptides, Peptide
transporter 2, Probenecid* Correspondence: smithb@umich.edu
1Department of Pharmaceutical Sciences, College of Pharmacy, University of
Michigan, Ann Arbor, Mi 48109, USA
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Chen et al. Fluids and Barriers of the CNS 2014, 11:25 Page 2 of 12
http://www.fluidsbarrierscns.com/content/11/1/25Background
Cephalosporins, a class of beta-lactam antibiotics, have
been widely used for the prophylaxis and treatment of a
variety of infections [1]. In addition to their antibacterial
activity, the therapeutic effects of different cephalosporins
depend on their pharmacokinetics and tissue distribution,
which are affected by multiple membrane transporters.
Some cephalosporins are substrates of proton-coupled
oligopeptide transporters (POTs) [2], organic anion trans-
porters (OATs) [3], organic anion transporting polypep-
tides (OATPs) [4,5], and multidrug resistance-associated
proteins (MRPs) [6,7]. These transporters are widely dis-
tributed in several tissues including the kidney, liver, intes-
tine, and brain [8], influencing cephalosporin absorption,
distribution, and elimination.
Among all tissues, drug delivery to brain is the most
challenging because of the blood–brain barrier (BBB),
situated at the cerebral endothelium, and blood-CSF
barrier (BCSFB) at the choroid plexus epithelium [9]. In
addition to tight junctions limiting paracellular diffusion
[10,11], the BBB and BCSFB express many transporters
responsible for chemical exchange between brain and
blood including efflux transporters important for pro-
tecting the brain from waste products and potential
toxins [12]. Among the cephalosporin transporters, the
MRPs and OATs at the BBB and BCSFB are believed to
transport substrates from brain (and CSF) to blood as ef-
flux transporters [13-15]. Peptide transporter 2 (PEPT2,
a member of POTs) at the apical side (CSF facing) of the
BCSFB is able to transport substrates from the CSF side
towards blood [16]. The OATPs are expressed both
at the BBB and BCSFB as bidirectional transporters
[17,18]. The above mentioned transporters are also
expressed on the cell membrane of brain cells (neurons,
astrocytes, and microglia) [13,14,18,19], potentially af-
fecting cephalosporin distribution after their entry into
brain. Thus, membrane transporters may influence the
brain distribution of cephalosporins and influence their
effectiveness for treating central nervous system (CNS)
infections.
Cefadroxil is a first-generation cephalosporin and used
clinically mainly to treat urinary tract infections [1]. The
current study employed cefadroxil as a model drug to
examine the potential impact of transporters on the
brain distribution of cephalosporins, as it has been re-
ported to be a substrate of POTs, OATs, MRPs, and
OATPs [5,6,20-22]. In small intestine, PEPT1, a member
of POTs, mediates peptide/mimetic uptake at the apical
side of enterocytes, leading to a high oral bioavailability
[23,24]. Thus, PEPT1 knockout led to a 23-fold reduction
in peak plasma concentrations and a 14-fold decrease in
systemic exposure of cefadroxil in mice [24]. Also, MRP3
and MRP4, at the basolateral side of enterocytes, may
contribute to the further transport of cefadroxil fromenterocyte to blood [22]. The kidney is the main elimin-
ation organ for cefadroxil and studies in PEPT2 null mice
indicate that this is the principal transporter involved in
cefadroxil reabsorption [20]. Moreover, the clearance of
cefadroxil is significantly reduced by co-administration of
probenecid [20,25]. Probenecid is widely known as an in-
hibitor of OATs, which mediates renal secretion at the
basolateral membrane of proximal tubule epithelia. How-
ever, probenecid can also inhibit the MRPs and OATPs
that transport substrates from blood to urine via the
kidney [26,27].
Studies on the distribution of cefadroxil in brain have
focused on the function of PEPT2 at the BCSFB and
brain cells. PEPT2 in choroid plexus removes cefadroxil
from CSF. As a result, the CSF-to-blood concentration
ratio of cefadroxil in wild-type mice was markedly lower
than that in PEPT2 knockout mice [20,28]. In addition,
cefadroxil inhibited the uptake of PEPT2 substrates in
rodent neonatal astrocytes, demonstrating an uptake
function of PEPT2 in brain cells [19,29,30]. However,
there are no studies on the influence of transporters on
the distribution of cefadroxil in brain extracellular fluid
(ECF). A deeper understanding of the effect of trans-
porters on CNS cephalosporin distribution is helpful for
the more efficient use of cephalosporins for treating
brain infections like meningitis.
The present study examined the impact of transporters
on cefadroxil distribution in brain ECF and CSF using
probenecid, an inhibitor of OATs, MRPs and OATPs, as
well as Ala-Ala, a substrate of PEPT2. In vivo microdial-
ysis was applied to measure cefadroxil concentrations in
rat brain ECF, CSF and blood. In addition, an in vitro
brain slice method was performed to study cefadroxil
distribution within the rat brain parenchyma.Methods
Chemicals
Cefadroxil, cefadroxil-D4 (deuterated), probenecid, Ala-Ala,
glycylsarcosine (GlySar), and amoxicillin were purchased
from Sigma-Aldrich (St. Louis, MO, USA), isoflurane from
Baxter Medical AB (Kista, Sweden), and 100 IU/mL hep-
arin from Leo Pharma AB (Malmö, Sweden). Acetonitrile
and formic acid were obtained from Merck (Darmstadt,
Germany). All other chemicals were of analytical grade or
better. Ringer’s solution was used to perfuse the microdialy-
sis probes and consisted of 145 mM NaCl, 0.6 mM KCl,
1.0 mM MgCl2, and 1.2 mM CaCl2 in 2 mM phosphate
buffer, pH 7.4. Artificial extracellular fluid (aECF), used to
buffer the brain slices, was comprised of 10 mM glucose,
129 mM NaCl, 3 mM KCl, 1.2 mM MgSO4, 0.4 mM
K2HPO4, 1.4 mM CaCl2, and 25 mM HEPES, pH 7.6, at
room temperature. Normal saline was obtained from Braun
Medical AB (Stockholm, Sweden) and the Milli-Q system
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the water.
Animals
Male Sprague–Dawley rats (260–300 g) were obtained
from Taconic (Lille Skensved, Denmark). Rats were ac-
climated for at least 7 days in a temperature- and
humidity-controlled environment with 12-hour light/
dark cycles before study. The protocols in this study
were approved by the Animal Ethics Committee of Uppsala
University, Sweden (C351/11 and C328/10).
Microdialysis study of cefadroxil in the absence and
presence of probenecid
Surgery was performed one day before microdialysis in
order to implant vessel catheters and microdialysis probes
as described previously [31] with modification. Briefly,
under isoflurane anesthesia and with body temperature
controlled at 38°C (CMA/150 temperature controller,
CMA, Stockholm, Sweden), catheters were inserted into
the left femoral vein for cefadroxil infusion, the left jugular
vein for control (Day 1) or probenecid infusion (Day 2),
and the left femoral artery for blood sampling. A CMA/20
probe with 10 mm polyarylethersulphone (PAES) mem-
brane was inserted into the right jugular vein. The rat was
then fixed on a stereotaxic frame equipped with an
anesthesia mask. Two guide cannulas were implanted into
the brain striatum (ST coordinates, +0.2 mm anteroposter-
ior, −4.7 mm lateral, −3.8 mm dorsoventral with an
angle of 15° at the coronal plane towards midline) and
lateral ventricle (LV coordinates, −0.9 mm anteropos-
terior, +1.6 mm lateral, −2.9 mm dorsoventral), and
fixed to the skull by a screw and dental cement. A
CMA 12 probe with 3 mm PAES membrane was
inserted into the striatal guide cannula for monitoring
brain ECF and a CMA 12 probe with 1 mm PAES
membrane was inserted into the ventricular guide cannula
for CSF sampling. At the end of the surgery, the rat was
placed in a CMA 120 system for freely moving animals in
which it had free access to food and water, and allowed to
recover for 24 hours before experimentation.
On Day 1, a 90-min stabilization period was per-
formed in which Ringer’s solution, containing cefadroxil-
D4, was perfused through the microdialysis probes by
pump (CMA 400, Solna, Sweden) at a flow rate of
0.5 μL/min. During this period, and throughout the
entire experiment (another 420 min), microdialysis sam-
ples (10 μL each) were collected every 20 min using a
fraction collector (CMA 142, Solna, Sweden) and stored
at 4°C until analysis. To quantify unbound drug concen-
trations in brain and blood, cefadroxil-D4 was used to
calibrate the probes using retrodialysis [32]. Because
cefadroxil levels in brain and blood were quite different,
1 μg/mL cefadroxil-D4 was used to perfuse the bloodprobe and 0.1 μg/mL for the brain probe. At 90 min,
cefadroxil solution (6 mg/mL in normal saline) was ad-
ministered intravenously (iv) as a bolus infusion of
0.3 mg/kg/min for 20 min followed by a constant-rate
infusion of 0.15 mg/kg/min for 160 min (for a total of
180 min). In addition to the microdialysis samples, arter-
ial blood samples (100 μL) were drawn predose and at 5,
18, 90, 150, 185, 190, 210, 240, 300, and 420 min after
initiating the cefadroxil bolus infusion. Plasma was har-
vested from blood after centrifuging at 7200 g for 5 min
and then frozen at −20°C until analysis. On Day 2, the
cefadroxil experiment was repeated, however, 15 mg/mL
probenecid in 5% NaHCO3 in saline (as opposed to 5%
NaHCO3 in saline only on Day 1) was added as a
20 mg/kg bolus followed by 20 mg/kg/hr infusion for
420 min (i.e., cefadroxil in the presence of probenecid).
Microdialysis study of cefadroxil in the absence and
presence of Ala-Ala
The surgery and microdialysis method for this study was
similar to that described before for probenecid except, in
this case, the dipeptide Ala-Ala was administered instead
and by intracerebroventricular (icv) infusion. In order to
perform the microdialysis sampling and icv infusion sim-
ultaneously, a microdialysis probe with an additional
infusion cannula passing through the lumen of probe (IBR
combination probe with 1 mm polyacrylanitrile mem-
brane, BASi, West Lafayette, IN, USA) was implanted into
the lateral ventricle (coordinates, −0.9 mm anteroposter-
ior, −1.6 mm lateral, −2.9 mm dorsoventral). For these
studies (i.e., cefadroxil in the absence and presence of Ala-
Ala), the experiment was performed in one day. In brief,
following the 90-min stabilization period, cefadroxil saline
solution was infused iv at 0.3 mg/kg/min for 20 min
followed by 0.15 mg/kg/min for 400 min (for a total of
420 min). An icv infusion of Ringer’s solution, 0.3 μL/min,
was started 30 min prior to cefadroxil administration and
maintained for another 240 min (control phase). At this
time, an icv infusion of 0.32 mg/mL Ala-Ala in Ringer’s
solution was started and then maintained for another
180 min.
In vitro brain slice study
The brain slice protocol was based on a previously pub-
lished method with minor modifications [33]. Briefly,
fresh brains were collected in which six 300-μm coronal
slices were prepared from each animal using a micro-
tome (Leica VT1200, Leica Microsystems AB, Sweden).
Resultant slices were transferred to an 80-mm diameter
beaker with 15 mL aECF containing 0.8 μM cefadroxil
with or without 5 mM GlySar, 5 mM Ala-Ala, or 1 mM
probenecid. Covered by a lid comprised of a Teflon fluo-
rinated ethylene-propylene film (DuPont, Katco Ltd,
UK), the beaker was incubated in a shaker (MaxQ4450,
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37°C, for 2 hr. Throughout the incubation, there was
a constant flow of oxygen into the shaking chamber
to maintain slice viability. After incubation, 200 μL
of blank rat brain homogenate without cefadroxil
was added to 200 μL of buffer sample to keep the
matrix consistent among all the samples for the fol-
lowing analysis. The brain slices were then weighed,
after drying on filter paper, and homogenized indi-
vidually in aECF (9:1 ratio, w/v) using an ultrasonic
processor (VCX-130, Sonics, Chemical Instruments
AB, Sweden). All samples were stored at −20°C until
analysis.
In all experiments, coronal slices were prepared
from the same anatomical plane corresponding to the
striatal region (no midbrain structures) in order to
avoid potential discrepancies in the assessment of the
unbound volume of distribution of cefadroxil in brain
(Vu,brain). In our studies, the Vu,brain values of cefa-
droxil were similar in each rat with little variability
(mean coefficient of variation ≤5.4%). Potential re-
gional differences in the Vu,brain of cefadroxil were
not studied.
Chemical analysis
The analysis of cefadroxil (and cefadroxil D-4) was car-
ried out using liquid chromatography–tandem mass
spectrometry (LC-MS/MS). Specifically, 5 μL microdi-
alysis samples were injected into the LC-MS/MS after
adding amoxicillin solution as an internal standard.
For plasma and homogenate samples, the proteins
were precipitated by adding acetonitrile at a ratio of
1:3. After centrifuging at 7200 g for 3 min, the super-
natant was diluted with 0.1% formic acid before inject-
ing into the LC-MS/MS. Standard curves and quality
control samples were used to quantify and validate the
concentrations of cefadroxil in all biological matrices
from the study.
Chromatographic separation was achieved on a HyPur-
ity C18 column (50 × 4.6 mm, particle size 3 μm) pro-
tected by a HyPurity C18 guard-column (10 × 4.0 mm,
particle size 3 μm; Thermo Hypersil-Keystone, PA, USA).
A gradient elution involving mobile phase A (0.1% formic
acid) and mobile phase B (0.1% formic acid in 1:1 aceto-
nitrile:water) was delivered by two Shimadzu LC-10ADvp
pumps (Shimadzu, Kyoto, Japan) at 0.8 mL/min, which
was split to 0.3 mL/min before entering the MS detector.
A Quattro Ultima Pt mass spectrometer (Waters, Milford,
MA, USA) was used for detection on positive electrospray
ionization (ESI+) mode. The transition mode was m/z
363.9→ 207.9 for cefadroxil, m/z 368.0→ 212.0 for
cefadroxil-D4, and m/z 366.0→ 348.9 for amoxicillin. All
data were acquired and processed using Masslynx 4.1
(Waters, Milford, MA, USA).Data analysis
The relative recovery of cefadroxil in each microdialysis
probe was estimated from retrodialysis of the calibrator,
cefadroxil-D4, and calculated as:
Re covery ¼ Cin;CEF−D4 −Cout;CEF−D4
Cin;CEF−D4
ð1Þ
where Cin,CEF-D4 is the concentration of cefadroxil-D4 in
perfusate and Cout,CEF-D4 is the concentration of
cefadroxil-D4 in dialysate. The unbound concentrations
of cefadroxil in blood (Cu,blood), brain ECF (Cu,ECF), and
CSF (Cu,CSF) were calculated from their respective con-
centrations in dialysate (Cdialysate) as:
Cu ¼ CdialysateRecovery ð2Þ
For the microdialysis study of cefadroxil (with and
without probenecid), the trapezoidal method was used
to calculate area under the curve for unbound cefadroxil
(AUCu) in blood, ECF, and CSF from 0–420 min. AUCu
values from 420 min to infinity were determined by ex-
trapolation from the time of the last measured concen-
tration Clast according to AUCextrapolated ¼ Clastλz , in which
λz is the terminal rate constant obtained from the slope
of the last 7 observations. The blood concentration of
cefadroxil at steady-state (Cu,ss,blood) was calculated from
the average of concentrations during the 120–180 min
time period. The unbound partition coefficient of cefa-
droxil in brain ECF (Kp,uu,ECF) and CSF (Kp,uu,CSF) was
obtained as follows:
Kp;uu;ECF ¼ AUCu;ECFAUCu;blood ð3Þ
Kp;uu;CSF ¼ AUCu;CSFAUCu;blood ð4Þ
Non-compartmental analyses were performed using
the microdialysis samples from blood to obtain the
pharmacokinetic parameters of unbound cefadroxil,
in which area under the moment curve (AUMCu)
was also obtained by trapezoidal method. The mean
input time (MIT) was 66 min calculated from MIT ¼
R01Tin21þR02Tin22
2 R01Tin1þR02Tin2ð Þ , where R0 and Tin denote the infu-
sion rate and infusion time of the two consecutive
cefadroxil infusions. With the correction of MIT, the
mean residence time with an iv bolus (MRTiv) was
obtained:
MRTiv ¼ AUMCu;0− inf
AUCu;0− inf
−MIT ð5Þ
The total clearance (CL), volume of distribution
steady-state (Vss), and half-life (t1/2) were calculated
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Vss ¼ CL MRTiv ð7Þ
t1=2 ¼ 0:693 MRTiv ð8Þ
For the microdialysis study of cefadroxil with and
without Ala-Ala, Kp,uu was calculated from the unbound







where Cu,ss was calculated during the 120–200 min time
period for the control phase (i.e., without Ala-Ala) and
during the 320–420 min time period for the dipeptide
phase (i.e., with Ala-Ala).
In analyzing brain slice data, the unbound volume of
distribution in brain (Vu,brain, in mL/g brain) was calcu-
lated for cefadroxil as:
Vu;brain ¼ Abrain − V i  CbufferCbuffer 1−V ið Þ ð10Þ
where Abrain is the total amount of cefadroxil in brain
slice, Cbuffer is the concentration of cefadroxil in buffer
at the end of incubation, and Vi is the volume of buffer
film surrounding the brain slice because of incomplete
adsorption by the filter paper; Vi was reported as
0.094 mL/g brain [34].
Statistical analysis
Data are expressed as mean ± SEM. A two-tailed paired
t-test was used to compare cefadroxil parameters be-
tween the control and inhibition phases. A value of
p <0.05 was considered statistically significant. For the
brain slice study, a one-way ANOVA with Dunnett’s test
was performed to compare each treatment group to the
control. GraphPad Prism v5.04 (GraphPad Software Inc.,
San Diego, CA) was used for all statistical analyses.
Results
Microdialysis study of cefadroxil in the absence and
presence of probenecid
There were no significant differences in probe relative
recoveries between the two days. The recoveries were
14 ± 1% for the 3-mm probe in brain ECF, 6.7 ± 1.1% for
the 1-mm probe in lateral ventricle, and 71 ± 2% for the
10-mm probe in blood. As shown in Figure 1A, steady-state concentrations of cefadroxil in blood were quickly
achieved after the bolus infusion of 0.3 mg/kg/min for
20 min followed by the constant-rate infusion of
0.15 mg/kg/min for 160 min. Compared to Day 1 (con-
trol phase), probenecid infusion increased Cu,ss,blood
and AUCu of cefadroxil by ~60%. The elevated sys-
temic exposure probably resulted from a decrease in
cefadroxil clearance from 16.9 ± 1.0 to 10.7 ± 0.7 mL/
min/kg (Table 1). However, the MRT and t1/2 did not
differ significantly between days, reflecting a reduced
volume of distribution (Vss) with probenecid, indicat-
ing probenecid may decrease the accumulation of
cefadroxil in certain tissues. Plasma cefadroxil concen-
trations (data not shown) were comparable to the
unbound blood concentrations from microdialysis, con-
sistent with previous studies showing that the unbound
fraction of cefadroxil in plasma (fu) is nearly 1.0 [35].
In addition to increasing unbound cefadroxil blood
concentrations, probenecid increased the AUCu of drug
in brain ECF 4-fold (p <0.05) and the AUCu of drug in
CSF 2-fold (p >0.05) (Figures 1B and 1C, and Table 1).
To determine if cefadroxil penetration into brain was
affected by probenecid, brain drug concentrations were
corrected by the corresponding values in blood (Figure 2).
During probenecid infusion (Day 2), the Cu,ECF values of
cefadroxil, relative to blood, were higher than control
(Day 1) at all time points. In contrast, the Cu,CSF values of
cefadroxil, relative to blood, were comparable. To evaluate
the effect of probenecid on cefadroxil penetration into
brain, the unbound partition coefficient Kp,uu was calcu-
lated for both brain ECF and CSF using AUCu values from
0–420 min and from 0-infinity (Figure 3). Kp,uu was
around 0.02 in both brain ECF and CSF in the control
situation, indicating limited penetration of cefadroxil into
brain and extensive efflux at the BBB (Table 1). Kp,uu,ECF
values were about 2.5-fold greater with probenecid treat-
ment as compared to control. In contrast, there were no
significant differences in Kp,uu,CSF between control and
probenecid treatments. This may reflect, in part, greater
experimental variability in the direction of change for this
parameter (Figures 3C and 3D).
Microdialysis study of cefadroxil in the absence and
presence of Ala-Ala
Recoveries were 16 ± 2%, 12 ± 1%, and 72 ± 1% for
probes in the striatum, lateral ventricle and blood, re-
spectively. Ala-Ala is a natural dipeptide that can be de-
graded in the body; thus, Ala-Ala was infused by the icv
route in order to achieve high concentrations in CSF.
The goal of the study was to determine if Ala-Ala affects
the distribution of cefadroxil by comparing levels in ECF
and CSF between vehicle control phase and during
Ala-Ala infusions. As shown in Figure 4, the unbound
concentrations of cefadroxil did not change substantially
Figure 1 The concentration-time profiles of unbound cefadroxil
in rat blood (A), brain ECF (B), and CSF (C) in the absence and
presence of probenecid. Open circles represent the results from
Day 1 (no probenecid) and solid circles the results from Day 2 (with
probenecid). Data are expressed as mean ± SEM (n = 6).
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more, there was no significant difference between
control and Ala-Ala infusions in Kp,uu,ECF (0.033 ± 0.004
to 0.041 ± 0.008, p = 0.15) or Kp,uu,CSF (0.038 ± 0.017 to
0.043 ± 0.016, p = 0.43).
In vitro brain slice study
Vu,brain describes the relationship between the total
amount of drug in brain and the unbound concentration
of drug in ECF, and is useful as a measure of intra-
parenchymal distribution [36]. A higher value Vu,brain
suggests that more drug accumulates inside the brain
cells. For control brain slices, the Vu,brain of cefadroxil
was 3.67 ± 0.23 mL/g brain (Figure 5). Two PEPT2
substrates, Ala-Ala and GlySar, reduced the Vu,brain ofTable 1 Pharmacokinetic parameters of unbound
cefadroxil in rat blood and brain on Day 1 (Control, Ctrl)
and Day 2 (with probenecid, Pro)
Parameters Unit Day 1 (Ctrl) Day 2 (Pro) Pro/Ctrl
Blood
AUCu (0–420) μg*min/mL 1747 ± 90 2801 ± 175*** 1.60
AUCu (0-inf) μg*min/mL 1802 ± 97 2873 ± 177*** 1.59
Cu,ss,blood μg/mL 8.5 ± 0.4 13.8 ± 0.9*** 1.62
MRTiv min 71 ± 4 77 ± 4 1.05
t1/2 min 49 ± 2 53 ± 3 1.09
CL mL/min/kg 16.9 ± 1.0 10.7 ± 0.7*** 0.63
Vss L/kg 1.19 ± 0.12 0.82 ± 0.10*** 0.69
Brain ECF
AUCu (0–420) μg*min/mL 31 ± 5 122 ± 31* 3.93
AUCu (0-inf) μg*min/mL 40 ± 7 174 ± 35** 4.37
Kp,uu,ECF (0–420) 0.018 ± 0.003 0.042 ± 0.009* 2.35
Kp,uu,ECF (0-inf) 0.022 ± 0.003 0.058 ± 0.009* 2.63
Brain CSF
AUCu (0–420) μg*min/mL 39 ± 12 73 ± 27 1.88
AUCu (0-inf) μg*min/mL 57 ± 15 117 ± 50 2.04
Kp,uu,CSF (0–420) 0.022 ± 0.006 0.024 ± 0.008 1.13
Kp,uu,CSF (0-inf) 0.031 ± 0.007 0.039 ± 0.015 1.26
Data are expressed as mean ± SEM (n = 6). A paired t-test was performed to
compare cefadroxil parameters between the control (without probenecid) and
treatment (with probenecid) phases of the study. *p < 0.05, **p < 0.01, and
***p < 0.001. Abbreviations: AUCu, Area under the unbound concentration-time
curve from time zero to 420 min (0–420) or from time zero to infinity (0-inf);
Cu,ss,blood, Unbound steady-state blood concentration; MRTiv, Mean residence
time; t1/2, Half-life; CL, Total clearance; Vss, Volume of distribution steady-state;
Kp,uu,ECF, Ratio of AUCu in brain ECF to AUCu in blood; and Kp,uu,CSF, Ratio of
AUCu in CSF to AUCu in blood.
Figure 2 The ratio of unbound cefadroxil in rat brain ECF (A) or
CSF (B) to that in blood versus time. Open circles represent the
results from Day 1 (no probenecid) and solid circles the results from
Day 2 (with probenecid). Data are expressed as mean ± SEM (n = 6).
Chen et al. Fluids and Barriers of the CNS 2014, 11:25 Page 7 of 12
http://www.fluidsbarrierscns.com/content/11/1/25cefadroxil to 0.95 ± 0.45 and 1.10 ± 0.05 mL/g brain, re-
spectively, indicating that they reduced the accumulation
of cefadroxil inside brain cells (p < 0.001). In contrast,
probenecid increased the Vu,brain of cefadroxil to 6.06 ±
0.15 mL/g brain, suggesting that probenecid led to more
accumulation of cefadroxil inside brain cells (p < 0.001).
Discussion
The current study used microdialysis and brain slice
methods to examine the transport mechanisms affecting
the distribution of cefadroxil, a cephalosporin antibiotic, in
brain. The results demonstrated that: 1) co-administration
of probenecid increased blood cefadroxil levels; 2) probene-
cid markedly increased brain ECF cefadroxil concentra-
tions; 3) the probenecid effect on brain ECF levels were
partially due to increased blood concentrations but alsodue to inhibition of cefadroxil efflux at the BBB (OATs,
OATPs and/or MRPs); 4) in contrast, increased CSF
cefadroxil concentrations with probenecid were only
due to elevated blood concentrations of antibiotic; 5)
intracerebroventricular infusion of the PEPT2 sub-
strate, Ala-Ala, did not increase brain ECF or CSF
cefadroxil levels; and 6) brain slice experiments dem-
onstrated that PEPT2 was involved in the uptake of
cefadroxil into brain cells and that probenecid blocked
a mechanism transporting cefadroxil out of cells.
In the interaction study between cefadroxil and pro-
benecid, intravenous co-administration of probenecid re-
duced the clearance of cefadroxil. This finding was
consistent with previous studies [20,25] showing that
probenecid inhibits the renal secretion of many cephalo-
sporins by OATs (and perhaps MRPs and OATPs) at the
kidney proximal tubule [37]. Even though steady-state
concentrations were achieved quickly for unbound cefa-
droxil in blood, steady-state concentrations in brain ECF
were not fully reached within the infusion period of
3 hr. As a consequence, Cu,ECF decreased more slowly
than Cu,blood after termination of the cefadroxil infusion.
The above phenomenon may be due to low permeability
of passive diffusion of cefadroxil at the BBB, considering
its high hydrophilicity. The Kp,uu of brain ECF is deter-
mined by the net influx and efflux clearances at the BBB,
as Kp,uu = CLin/CLout [36]. If only passive transport oc-
curs at the BBB, Kp,uu is equal to unity due to the equal
values for CLin and CLout. However, the Kp,uu,ECF of cefa-
droxil was about 0.02, indicating that cefadroxil CLout is
much higher than CLin. Thus, it appears that there is net
efflux transport for cefadroxil at the BBB. It has been re-
ported that cefadroxil is a substrate of OATs and MRPs
[6,21,22]. Specifically, OAT3 located at the basolateral
(abluminal) side of the BBB and MRPs at the apical (lu-
minal) side of the BBB mediate brain-to-blood transport
as efflux transporters, thus possibly contributing the low
Kp,uu,ECF of cefadroxil [13,15,38]. Inhibition of OAT3
and/or MRPs at the BBB is the probable reason why
probenecid increased the Kp,uu,ECF of cefadroxil ~2.5
fold. In addition to OATs and MRPs, cefadroxil was re-
ported to be a substrate of OATPs. However, OATPs are
bidirectional transporters [12,17,18] and their net effect
on cefadroxil transport at the BBB is unknown. A sche-
matic representation of the membrane transporters in-
volved in the CNS distribution of cefadroxil is shown in
Figure 6.
OATs and MRPs [13,14] are also responsible for the
transport of substrates from CSF to blood at the BCSFB.
Therefore, it was expected that inhibition of OATs and
MRPs by probenecid would increase the Kp,uu,CSF of
cefadroxil. However, no significant change was found
for this parameter. The differential effect of transporter
inhibition by probenecid on the distribution of cefadroxil
Figure 3 The unbound partition coefficient (Kp,uu) of cefadroxil in rat brain ECF (A, B) and CSF (C, D) for each of the six animals. CEF
represents the study in which cefadroxil is given alone (Day 1) and CEF + PRO is when cefadroxil is given in the presence of probenecid (Day 2).
See Table 1 for statistical analyses.
Figure 4 The concentration-time profiles of unbound cefadroxil
in rat blood, brain ECF, and CSF in the absence and presence
of Ala-Ala. Solid squares represent the results in blood, open circles
the results in brain ECF, and solid triangles the results in CSF. The
vertical dashed line separates the two treatment phases (CEF ± Ala-Ala).
Data are expressed as mean ± SEM (n = 7).
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logical and structural differences between BBB and
BCSFB. The complement of efflux transporters, their ex-
pression levels, and cellular location may affect the rela-
tive importance of individual transporters in each of the
two systems. In addition, the endothelial BBB is tighter
than the epithelial BCSFB (choroid plexus), affecting
paracellular diffusion [42]. A recent study on the effects
of probenecid on methotrexate transport found a differ-
ent modulation of methotrexate distribution in brain
ECF and CSF [43]. There was a dose-dependent effect,
in which probenecid increased the brain ECF-to-plasma
ratio for two dose regimens of methotrexate (40 mg/kg
and 80 mg/kg), whereas probenecid only significantly in-
creased the CSF-to-plasma ratio at the higher dose [43].
The differential effects of probenecid on cefadroxil at
the BBB and BCSFB in our study are unlikely to be due
to differences in inhibitor concentration at the two sites
as Deguchi et al. [44] found higher probenecid concen-
trations in CSF than ECF after systemic dosing.
In a previous study, PEPT2 ablation resulted in a
marked increase in the CSF-to-blood concentration ratio
of cefadroxil, indicating the importance of PEPT2 in
eliminating cefadroxil from CSF at the BCSFB [20].
However, in the present study, an icv infusion of the
PEPT2 substrate Ala-Ala did not significantly change
CSF cefadroxil concentrations. This lack of effect may
reflect insufficient concentrations of Ala-Ala reachingthe BCSFB. Ala-Ala was chosen to inhibit PEPT2 be-
cause it has a relatively high affinity for that transporter
(Ki = 6.3 μM, similar to that of cefadroxil with a Ki =
3.0 μM) [2]. However, Ala-Ala has the disadvantage of
being degraded by peptidases, many of which are found
in the choroid plexus and brain [45].
Figure 5 The unbound volume of distribution of cefadroxil
(Vu,brain) in rat brain slices. Studies were performed with 0.8 μM
cefadroxil alone (Control) and in the presence of inhibitors (Ala-Ala,
GlySar and Probenecid treatments). Data are expressed as mean ±
SEM (n = 3-4). One-way ANOVA followed by the Dunnett’s test was
performed to compare the inhibitor and control phases. ***p < 0.001
compared to control.
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parenchyma. The water volume in brain parenchyma is
0.8 mL/g brain and a Vu,brain of around 0.8 mL/g brain
indicates a drug is distributed evenly through the whole
brain tissue [36]. From a previous study using equilibriumFigure 6 Membrane transporters (potentially) involved in the CNS dis
schematic representation [16,39-41]. There is much debate regarding the is
though, considerable evidence for some MRPs having an apical distribution
evidence for the probenecid-inhibitable efflux of cefadroxil from brain cells
MRP and/or OATP transporters. BL represents the basolateral membrane, Adialysis in brain homogenate (data not published), cefa-
droxil had a fraction unbound (fu) of nearly 1, indicating
little, if any, drug binding to brain tissues. This, together
with the cefadroxil Vu,brain of 3.67 mL/g brain in the present
study indicates the presence of uptake transporter(s) at the
membrane of brain cells. The PEPT2 substrates, 5 mM
Ala-Ala and GlySar, reduced the Vu,brain of cefadroxil, indi-
cating that competitive inhibition of PEPT2 decreased the
uptake of cefadroxil into brain cells. This is consistent with
previous findings that PEPT2 is expressed on neurons and
responsible for cellular uptake [46]. In contrast, probenecid
increased the Vu,brain of cefadroxil, indicating there may also
be efflux transporters (e.g., OATs, MRPs or OATPs) remov-
ing cefadroxil from brain cells. Interestingly, a previous
study demonstrated that probenecid increased the intracel-
lular levels of valproic acid by 1.5-fold in rabbit brain dur-
ing in vivomicrodialysis [47].
By using intracerebral microdialysis in vivo and brain
slices in vitro, a better understanding was obtained about
the effect of transporters on cefadroxil distribution in
brain and, specifically, in brain extracellular and intracellu-
lar fluids, and CSF. From our study, it appears that trans-
porters which are probenecid inhibitable (i.e., OATs,
MRPs and/or OATPs) move cefadroxil in a vectorial direc-
tion from brain ECF to blood, and that PEPT2 transports
cefadroxil into brain cells. In addition, as probenecid in-
creased cefadroxil uptake into brain slices, there is an as
yet unidentified cefadroxil transporter effluxing this ceph-
alosporin from brain cells. It is concluded that multiple
transporters play a role in the distribution of cefadroxiltribution of cefadroxil. Several references were used to inform this
oforms and membrane localization of MRPs at the BBB. There is,
clearing substrates to blood as depicted. There is also functional
, the nature of which is uncertain but may include OAT,
P the apical membrane, and EP the ependyma.
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porters on specific cephalosporins will depend on trans-
porter affinities and drug levels in brain. Microdialysis is a
useful tool to study the kinetics of unbound drug concen-
trations in ECF and CSF [48]. The brain slice method,
together with other tools like equilibrium dialysis, provides
an approach to study the distribution of drugs within
brain after passing the BBB and BCSFB [34,49].
A deeper understanding of the brain distribution of
cephalosporins may aid in the better use of these anti-
bacterial agents for the prophylaxis and treatment of
CNS infections. Bacterial meningitis is an inflammatory
process of the leptomeninges caused by bacterial infec-
tions. Bacterial meningitis is the most frequent CNS in-
fection with a mortality rate approaching 20% [50]. It is
believed that bacteria enter the CNS across BBB or
BCSFB via transcytosis and finally enter the CSF [50].
Even though BBB permeability increases during menin-
gitis [51], the barriers and their efflux transporters still
play a role in limiting cephalosporin entry to brain. Clin-
ically, the cephalosporins used for meningitis are limited
to ceftriaxone, cefotaxime, ceftazidime, and cefepime,
which have high penetration into CSF [52]. Another
CNS infection is cerebritis, a focal brain parenchyma in-
fection, which is often followed by brain abscesses and
permanent damage [53]. Treatment for cerebritis and
brain abscesses also involves antibiotics. The strategy of
blocking the related efflux transporters at the BBB and
BCSFB is a promising way to enhance the penetration of
relevant cephalosporins into brain ECF and CSF.
Probenecid was firstly widely used to decrease renal
clearance of penicillin during World War II, when anti-
biotic supplies were low. Probenecid decreases the elim-
ination rate and volume of distribution for a variety of
medications including most cephalosporins [54]. How-
ever, with easier and cheaper production of antibiotics,
probenecid is now seldom used with antibiotics. The
present study showed that probenecid was able to in-
crease the distribution of cefadroxil in brain ECF not
only by reducing the renal clearance (and increasing sys-
temic exposure) but also by specifically increasing the
penetration into brain (i.e., increased Kp,uu) and further
into brain cells. It should be appreciated that, although
this study was not designed to study cefadroxil under
clinical dosing conditions, the co-administration of pro-
benecid allowed cefadroxil to reach the lower limit of its
minimal inhibitory concentration in brain ECF for some
bacteria (i.e., about 0.4 μg/mL). Thus, the combined
therapy of cefadroxil (or perhaps other cephalosporins)
and probenecid might be useful for some cases of men-
ingitis and brain abscesses. Whether or not this ap-
proach is feasible would depend upon the extent of this
drug-drug interaction in patients during different dosing
combinations of both antibiotic and the inhibitor.Moreover, there is a delicate balance between the dose–
response relationships of bacterial kill and CNS toxicity,
which of course would have to be taken into account.Conclusions
Using in vivo microdialysis and in vitro brain slice
methods in rat, the present study demonstrated that
probenecid increased cefadroxil distribution into brain
extracellular and intracellular fluids by blocking related
efflux transporters at the BBB and brain cells. Our find-
ings suggest that the combination of probenecid and
some cephalosporins may provide a strategy to increase
therapeutic drug levels in brain for better treatment of
CNS infections like bacterial meningitis and brain ab-
scesses. On the other hand, since multiple transporters
are involved in transporting cephalosporins in brain,
there is also the potential for drug-drug interactions to
enhance cephalosporin-induced neurotoxicity.
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